NO170489B - INTERMEDIATE FOR THE PREPARATION OF ACE INHIBITORS - Google Patents
INTERMEDIATE FOR THE PREPARATION OF ACE INHIBITORS Download PDFInfo
- Publication number
- NO170489B NO170489B NO872226A NO872226A NO170489B NO 170489 B NO170489 B NO 170489B NO 872226 A NO872226 A NO 872226A NO 872226 A NO872226 A NO 872226A NO 170489 B NO170489 B NO 170489B
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compound
- carboxy
- stands
- lower alkoxycarbonyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 8
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title description 7
- 239000005541 ACE inhibitor Substances 0.000 title description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 22
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000001953 recrystallisation Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- YQOUMBVFEWZLME-VOTSOKGWSA-N (e)-2-oxo-4-phenylbut-3-enoic acid Chemical compound OC(=O)C(=O)\C=C\C1=CC=CC=C1 YQOUMBVFEWZLME-VOTSOKGWSA-N 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 2
- 230000036571 hydration Effects 0.000 claims description 2
- 238000006703 hydration reaction Methods 0.000 claims description 2
- 239000000047 product Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ARGCQEVBJHPOGB-UHFFFAOYSA-N 2,5-dihydrofuran Chemical group C1OCC=C1 ARGCQEVBJHPOGB-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- -1 R-N-[2,5-dihydro-2-oxo-5-phenyl-3-furanyl]amine Chemical compound 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CRPCSEZDTZRRFH-NSHDSACASA-N ethyl 2-[(3s)-3-amino-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetate Chemical compound C1C[C@H](N)C(=O)N(CC(=O)OCC)C2=CC=CC=C21 CRPCSEZDTZRRFH-NSHDSACASA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- YPRFGPKFFMJKRB-UHFFFAOYSA-N lead;propan-2-one Chemical compound [Pb].CC(C)=O YPRFGPKFFMJKRB-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Foreliggende oppfinnelse vedrører en ny fremgangsmåte for fremstilling av ACE-inhibitorer, hvor ved det anvendes billigere utgangsmaterialer og mindre toksiske reagenser og som, i motsetning til den vanlige syntesen, tillater en enkel, effektiv og billig diastereomeradskillelse. The present invention relates to a new method for the production of ACE inhibitors, where cheaper starting materials and less toxic reagents are used and which, in contrast to the usual synthesis, allows a simple, efficient and cheap diastereomer separation.
Hittil har de angiotensin-omvandlende enzym-inhibitorne (ACE-inhibitorne) av formel I, Until now, the angiotensin-converting enzyme inhibitors (ACE inhibitors) of formula I,
hvori R<*> står for karboksy og E^ står for karboksy eller laverealkoksykarbonyl, fremstilt ved en kostbar, tidkrevende fremgangsmåte med mange trinn, hvilket krevde tallrike rensetrinn og til slutt en Borsch reduksjon og en ytterst, vanskelig diastereomeradskillelse. Enkelthetene ved denne fremgangsmåten fremgår av U.S. patentene 4,410,520 og 4,473,575. En spesifikk syntesveg er gjengitt i litteraturen i "Drugs of the Future", bind 9, nr. 5, 1984. in which R<*> stands for carboxy and E^ stands for carboxy or lower alkoxycarbonyl, prepared by an expensive, time-consuming process with many steps, which required numerous purification steps and finally a Borsch reduction and an extremely difficult diastereomer separation. The details of this method appear in U.S. Pat. patents 4,410,520 and 4,473,575. A specific route of synthesis is reproduced in the literature in "Drugs of the Future", Volume 9, No. 5, 1984.
Det er et formål med foreliggende oppfinnelse å tilveiebringe It is an object of the present invention to provide
en synteseveg for fremstilling av angiotensin-omvandlende enzyminhibitorer ((ACEI) av formel I, eller salter derav, som er enkel og billigere enn de kjente fremgangsmåtene. a synthetic route for the production of angiotensin-converting enzyme inhibitors ((ACEI)) of formula I, or salts thereof, which is simple and cheaper than the known methods.
Det er et ytterligere formål med oppfinnelsen å tilveiebringe It is a further object of the invention to provide
en synteseveg for ACEI som tillater rask adskillelse av diastereomere produkter. a synthetic pathway for ACEIs that allows rapid separation of diastereomeric products.
Det er et ytterligere formål med oppfinnelsen å tilveiebringe It is a further object of the invention to provide
en ACEI-synteseveg hvorved anvendelsen av tallrike meget an ACEI synthesis pathway whereby the application of numerous very
toksiske reagenser unngås, hvilket er nødvendige i den kjente syntesen. toxic reagents are avoided, which are necessary in the known synthesis.
Disse og ytterligere viktige fordeler oppnås ved foreliggende oppfinnelse hvorved de tilsvarende ACE-inhibitorene fremstilt med utgangspunkt i 2-okso-4-fenyl-trans-3-butensyre, ved at denne kondenseres med et egnet amin R-NH2• på denne måten oppnås det nye mellomproduktet R-N-[2,5-dihydro-2-okso-5-fenyl-3-furanyl]aminet. Denne forbindelsen hydreres deretter hvorved furanylringen mettes og åpnes. Den oppnådde hydr-oksyfunksjonen på benzylenheten hydreres, slik at det oppstår en diastereomer racemisk blanding som kan adskilles i de i det vesentlige rene (S,S) diastereomerene ved at produktet omkrystalliseres fra acetonitril og oppslemmes deri. These and further important advantages are achieved by the present invention whereby the corresponding ACE inhibitors are prepared starting from 2-oxo-4-phenyl-trans-3-butenoic acid, by condensing this with a suitable amine R-NH2• in this way, the new intermediate R-N-[2,5-dihydro-2-oxo-5-phenyl-3-furanyl]amine. This compound is then hydrogenated whereby the furanyl ring is saturated and opened. The obtained hydroxy function on the benzyl unit is hydrogenated, so that a diastereomeric racemic mixture occurs which can be separated into the essentially pure (S,S) diastereomers by recrystallizing the product from acetonitrile and slurping therein.
Foreliggende oppfinnelse vedrører en fremgangsmåte for fremstilling av formel I The present invention relates to a method for producing formula I
hvori R<1> står for karboksy og R<2> står for karboksy eller wherein R<1> stands for carboxy and R<2> stands for carboxy or
lavere-alkoksykarbonyl, eller et salt derav, kjennetegnet ved lower alkoxycarbonyl, or a salt thereof, characterized by
a) omsetning av en forbindelse av formel (II) a) conversion of a compound of formula (II)
hvori Ri er karboksy eller lavere alkoksykarbonyl, med trans-2-okso-4-fenyl-3-butensyre i nærvær av en alkohol, slik at det oppnås en forbindelse av formel (III) b) ved katalyttisk hydrering av forbindelsen av formel III i nærvær av en alkohol, c) ved omkrystallisering av det oppnådde hydreringsproduktet fra acetonitril eller oppslemming i acetonitril, slik at det oppnås en forbindelse av formel I hvori R<2> står for karboksy, d) ved tilsats av saltsyre når en forbindelse av formel I er ønsket hvori R<*> og R<2> står for karboksy, hvorved dette trinnet c) bare er påkrevet dersom R^ i forbindelsen av formel II og III er laverealkoksykarbonyl, og e) når en forbindelse av formel I er ønsket hvori R<1> står for karboksy og R<2> for laverealkoksykarbonyl, ved videre omsetning av produktet fra trinn b) med en laverealkanol i nærvær av tionylklorid og .omsetning av det derved oppnådde produktet med 4N saltsyre eller med IN natriumhydroksyd eller kaliumhydroksyd, hvorved laverealkoksykarbonyl-gruppen R<* >forsåpes selektivt. wherein Ri is carboxy or lower alkoxycarbonyl, with trans-2-oxo-4-phenyl-3-butenoic acid in the presence of an alcohol, so that a compound of formula (III) b) is obtained by catalytic hydrogenation of the compound of formula III in presence of an alcohol, c) by recrystallization of the obtained hydration product from acetonitrile or suspension in acetonitrile, so that a compound of formula I is obtained in which R<2> stands for carboxy, d) by addition of hydrochloric acid when a compound of formula I is desired in which R<*> and R<2> stand for carboxy, whereby this step c) is only required if R^ in the compound of formula II and III is lower alkoxycarbonyl, and e) when a compound of formula I is desired in which R <1> stands for carboxy and R<2> for lower alkoxycarbonyl, by further reacting the product from step b) with a lower alkanol in the presence of thionyl chloride and reacting the product thus obtained with 4N hydrochloric acid or with 1N sodium hydroxide or potassium hydroxide, whereby lower alkoxycarbonyl - the group R<* >is selectively saponified.
I det foregående og etterfølgende har de anvendte defini-sjonene følgende betydninger: R er resten [l]-benzasepin-2-on-(3S)-3-yl, som i 1-posi-sjonen, dvs. på ring-nitrogenatomet, er substituert med R<*->CH2. In the foregoing and subsequent, the definitions used have the following meanings: R is the residue [1]-benzazepin-2-one-(3S)-3-yl, as in the 1-position, i.e. on the ring nitrogen atom, is substituted with R<*->CH2.
Bortsett fra i forbindelser av formel I, hvori R<1> utelukkende betyr karboksy, er R<1> og R<2>, uavhengig av hverandre, karboksy eller laverealkoksykarbonyl. Except in compounds of formula I, in which R<1> is exclusively carboxy, R<1> and R<2> are independently carboxy or lower alkoxycarbonyl.
Begrepet "lavere" definerer grupper med opp til og med 7 karbonatomer, fortrinnsvis med opp til og med 4 karbonatomer og spesielt foretrukket med 1 eller 2 karbonatomer. The term "lower" defines groups with up to and including 7 carbon atoms, preferably with up to and including 4 carbon atoms and particularly preferably with 1 or 2 carbon atoms.
Laverealkoksykarbonyl er f.eks. metoksykarbonyl, etoksykarbonyl, propoksykarbonyl eller butoksykarbonyl, som tert-butoksykarbonyl. Lower oxycarbonyl is e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or butoxycarbonyl, such as tert-butoxycarbonyl.
Salter av forbindelser av formel I kan dannes med syrer eller baser og er fortrinnsvis farmasøytisk tålbare salter, som med halogenhydrogensyrer, f.eks. med saltsyre, eller med syrene og basene som er beskrevet i U.S. patent nr. 4,410,520. Salts of compounds of formula I can be formed with acids or bases and are preferably pharmaceutically acceptable salts, such as with hydrohalogen acids, e.g. with hydrochloric acid, or with the acids and bases described in U.S. Patent No. 4,410,520.
Den aktuelle delen av beskrivelsen i dette U.S. patentet er hermed innbefattet som referanse. The applicable portion of the description in this U.S. the patent is hereby incorporated by reference.
Fremgangsmåten ifølge oppfinnelsen omfatter følgelig omsetning av et amin av formel II The method according to the invention therefore comprises reacting an amine of formula II
med trans-2-okso-4-fenyl-3-butensyre i nærvær av en alkohol, fortrinnsvis en laverealkanol, spesielt etanol, slik at det oppnås et nytt mellomprodukt av formel III with trans-2-oxo-4-phenyl-3-butenoic acid in the presence of an alcohol, preferably a lower alkanol, especially ethanol, so that a new intermediate of formula III is obtained
R<1> står her for karboksy eller laverealkoksykarbonyl. En fremgangsmåte hvor det istedet for en forbindelse av formel II anvendes aniliner, er beskrevet i J. Org. Chem. 33, 3991-3993 (1968). R<1> here stands for carboxy or lower alkoxycarbonyl. A method where anilines are used instead of a compound of formula II is described in J. Org. Chem. 33, 3991-3993 (1968).
Mellomproduktet av formel III hydreres deretter katalyttisk i nærvær av en alkohol, fortrinnsvis en laverealkanol, og spesielt etanol, til en forbindelse av formel IV The intermediate of formula III is then catalytically hydrogenated in the presence of an alcohol, preferably a lower alkanol, and especially ethanol, to a compound of formula IV
Hydreringsreaksjonen metter dobbeltbindingen i 2,5-dihydro-furanringen og bryter opp laktonbindingen, hvorved ringen åpnes. Idet dette fører til en benzylisk hydroksyfunksjon går hydreringen videre, slik at produktet formel IV oppnås. Selv om de fleste hydreringskatalysatorne prinsippielt kommer på tale er en palladium-karbonkatalysator spesielt foretrukket . The hydrogenation reaction saturates the double bond in the 2,5-dihydro-furan ring and breaks up the lactone bond, thereby opening the ring. As this leads to a benzylic hydroxy function, the hydrogenation proceeds, so that the product formula IV is obtained. Although most hydrogenation catalysts are in principle suitable, a palladium-carbon catalyst is particularly preferred.
Et overraskende og viktig trekk ved oppfinnelsen er den omstendigheten at adskillelsen av den S,SR racemiske blandingen til de ønskede S,S forbindelsene av formel I kan gjennomføres enkelt og raskt, ved at blandingen omkrystalliseres fra acetonitril eller oppslemmes i acetonitril. S,S diastereomeren oppnås vanligvis i en renhet på mer enn 98$. A surprising and important feature of the invention is the fact that the separation of the S,SR racemic mixture into the desired S,S compounds of formula I can be carried out simply and quickly, by the mixture being recrystallized from acetonitrile or slurried in acetonitrile. The S,S diastereomer is usually obtained in a purity greater than 98%.
Når R<2> i den ønskede forbindelsen av formel I står for karboksy og R<1> allerede i utgangsmaterialet har betydningen karboksy, er fremgangsmåten avsluttet etter omkrystalli-seringen fra, eller oppsiemmingen med, acetonitril. Når på den andre siden R<1> opprinnelig står for laverealkoksykarbonyl gir omsetningen med f.eks. hydrogenklorid det ønskede produktet. Når det ønskede produktet skal oppvise R<2> som laverealkoksykarbonyl kan produktet fra krystallisasjons-eller oppslemmingstrinnet omsettes med den ønskede lavere-alkanolen, spesielt med etanol, i nærvær av tionylklorid. Ytterligere behandling av dette produktet med f.eks. ca. 4N saltsyre eller med et ca. IN alkalimetallhydroksyd, som natrium- eller kaliumhydroksyd, ved ca. 50°C i minst 1 time, setter selektivt R^ karboksygruppen fri, uten at R<2> esteren påvirkes. Videregående behandling med syre eller base setter deretter også R<2> karboksygruppen fri. Som syrer eller baser er her igjen saltsyre eller alkalimetallhydroksyder, som natrium- eller kaliumhydroksyd egnede. When R<2> in the desired compound of formula I stands for carboxy and R<1> already in the starting material has the meaning carboxy, the process is finished after recrystallization from, or sieving with, acetonitrile. When, on the other hand, R<1> originally stands for lower alkoxycarbonyl, the reaction with e.g. hydrogen chloride the desired product. When the desired product is to exhibit R<2> as lower alkoxycarbonyl, the product from the crystallization or slurry step can be reacted with the desired lower alkanol, especially with ethanol, in the presence of thionyl chloride. Further treatment of this product with e.g. about. 4N hydrochloric acid or with an approx. IN alkali metal hydroxide, such as sodium or potassium hydroxide, at approx. 50°C for at least 1 hour, selectively sets R^ the carboxyl group free, without affecting the R<2> ester. Further treatment with acid or base then also sets the R<2> carboxyl group free. As acids or bases, here again hydrochloric acid or alkali metal hydroxides, such as sodium or potassium hydroxide, are suitable.
Når en forbindelse av formel I er ønsket hvori R<2> står for den frie karboksygruppen er alle alkoholer egnede som temporære forestringsgrupper for R<2>, dersom de på andre steder ikke reagerer med resten av molekylet og på kjent måte kan fjernes igjen uten problemer. Idet den frie R<1> karboksygruppen er ønsket i forbindelser av formel I, er en hvilken som helst forestrende gruppe egnet for R<*> karboksygruppen i utgangsmaterialet, forutsatt at den lett kan fjernes igjen, selv om slike grupper her ikke skal angis enkeltvis. When a compound of formula I is desired in which R<2> stands for the free carboxy group, all alcohols are suitable as temporary esterification groups for R<2>, if they do not react with the rest of the molecule elsewhere and can be removed again in a known manner without problems. Since the free R<1> carboxy group is desired in compounds of formula I, any esterifying group is suitable for the R<*> carboxy group in the starting material, provided that it can be easily removed again, although such groups are not to be indicated here individually .
Oppfinnelsen skal i det følgende beskrives nærmere ved hjelp av eksempler. In the following, the invention will be described in more detail by means of examples.
Eksempel 1; Example 1;
a) Fremstilling av etyl- 3- 1" ( 2 . 5- dihydro- 2- okso- 5- fenyl- 5S- 3-furanyl) aminoi- 2. 3, 4. 5- tetrahydro- 2- okso-( 3S)- ri" l-benzazepin- l- acetat av formel III a) Preparation of ethyl-3-1"(2.5-dihydro-2-oxo-5-phenyl-5S-3-furanyl)aminoi-2.3,4.5-tetrahydro-2-oxo-(3S) - ri"l-benzazepine-l-acetate of formula III
Til en oppløsning av 0,935 g (0,0055 mol) 2-okso-4-fenyl-trans-3-butensyre i 8-10 ml kald etanol tilsettes ved 0°C dråpevis under omrøring en etanolisk oppløsning av 1,3 g (0,005 mol) etyl-3-amino-2,3,4,5-tetrahydro-2-okso-(3S)-[l]-benzazepin-l-acetat. Etter avslutning av tilsatsen omrøres blandingen ved 20°C i 1 time, deretter får temperaturen stige til romtemperatur. Etter 20-48 timer utfelles produktet og kan frafUtreres. Det oppnås på denne måten mellom 60 og 90% av det ønskede produktet, avhengig av reaksjonstiden og temperaturen. Produktet har et smeltepunkt på 144-146"C (rå) eller 146-148°C etter omkrystallisasjon. An ethanolic solution of 1.3 g (0.005 mol) ethyl 3-amino-2,3,4,5-tetrahydro-2-oxo-(3S)-[1]-benzazepine-1-acetate. After completion of the addition, the mixture is stirred at 20°C for 1 hour, then the temperature is allowed to rise to room temperature. After 20-48 hours the product precipitates and can be removed. Between 60 and 90% of the desired product is obtained in this way, depending on the reaction time and temperature. The product has a melting point of 144-146"C (raw) or 146-148°C after recrystallization.
b) Fremstilling av forbindelsen ifølge formel I hvori R-*- er COOEt og R<2> er COOH b) Preparation of the compound according to formula I in which R-*- is COOEt and R<2> is COOH
Det umettede aminolactonet av formel III (25 g, 0,06 mol) suspenderes i etanol (1500 ml). Det tilsettes 4 Å molekylar-sikt (50 g) og 5 g 5% palladium på karbon. Blandingen hydreres ved romtemperatur i ca. 20 timer inntil den teo-retiske mengden hydrogen er forbrukt. Reaksjonsblandingen filtreres for å fjerne katalysatoren og molekylarsikten, og filterkaken vaskes med frisk etanol (ca. 1000 ml). De samlede filtratene filtreres på nytt over "Celite" og inndampes slik at det oppnås 25 g av et hvitt, fast stoff (råprodukt). Råproduktet omkrystalliseres fra acetonitril (ca. 200 ml, 80°C) og avkjøles, slik at 8,3 g (første prosjon) av S,S diastereomeren av formel I oppnås, hvori R<1 >er COOEt og R<2> er C00H, smeltepunkt 185-186°C; [a]g<5> = The unsaturated aminolactone of formula III (25 g, 0.06 mol) is suspended in ethanol (1500 mL). 4 Å molecular sieve (50 g) and 5 g of 5% palladium on carbon are added. The mixture is hydrated at room temperature for approx. 20 hours until the theoretical amount of hydrogen is consumed. The reaction mixture is filtered to remove the catalyst and the molecular sieve, and the filter cake is washed with fresh ethanol (about 1000 ml). The combined filtrates are filtered again over "Celite" and evaporated so that 25 g of a white, solid substance (crude product) is obtained. The crude product is recrystallized from acetonitrile (ca. 200 ml, 80°C) and cooled, so that 8.3 g (first fraction) of the S,S diastereomer of formula I is obtained, in which R<1> is COOEt and R<2> is C00H, melting point 185-186°C; [a]g<5> =
-156,87° ( 1% i etnaol). -156.87° (1% in ethanol).
c) Fremstilling av forbindelsen som tilsvarer formel I hvori R1 oa R<2> begge er COOEt c) Preparation of the compound corresponding to formula I in which R1 and R<2> are both COOEt
Til en suspensjon av forbindelsen som er beskrevet under b) For a suspension of the compound described under b)
[8,0 g (0,0188 mol) i etanol (ca. 80 ml), avkjølt itl 6°C] [8.0 g (0.0188 mol) in ethanol (approx. 80 ml), cooled to 6°C]
tilsettes dråpevis tionylklorid (3,2 ml, 4,88 g, 0,41 mol). På denne måten oppnås en klar oppløsning. Blandingen oppvarmes i ca. 40 timer under tilbakeløp. Deretter under-søkes blandingen tynnsjiktkrommatografisk med toluen/eddikester (1:1) og eddikester, metanol, ammoniumhydroksydopp-løsning (17:3:3). Omsetningen viser seg å være mer enn 90$ fullstendig. Blandingen inndampes til tørrhet. Man oppnår råproduktet som ifølge HPLC-analyse inneholder mer enn 91% ren S,S diastereomer av formel I, hvori R<*> og R<2> begge står for COOEt. thionyl chloride (3.2 ml, 4.88 g, 0.41 mol) is added dropwise. In this way, a clear resolution is achieved. The mixture is heated for approx. 40 hours during reflux. The mixture is then examined by thin-layer chromatography with toluene/acetic ester (1:1) and ethyl acetate, methanol, ammonium hydroxide solution (17:3:3). The turnover turns out to be more than 90$ completely. The mixture is evaporated to dryness. The crude product is obtained which according to HPLC analysis contains more than 91% pure S,S diastereomer of formula I, in which R<*> and R<2> both stand for COOEt.
d) Fremstilling av forbindelsen av formel I hvori R-*- står for COOH og R<2> står for COOEt ( alkaliske betingelser) d) Preparation of the compound of formula I in which R-*- stands for COOH and R<2> stands for COOEt (alkaline conditions)
Til en oppløsning av den under c) omtalte diesteren (1 g, 0,002 mol) i etanol (10 ml) tilsettes en oppløsning av natriumkarbonat (212 mg, 0,002 mol) i 8 ml vann, deretter en 1-molar oppløsning av natriumhydroksyd (1,8 ml, 0,0018 mol). Blandingen omrøres ved romtemperatur og kontrolleres ved EPLC (C^g-søyle under anvendelse av en vann -+ metanolgradient i løpet av 20 minutter). Når reaksjonen er fullstendig avsuges etanolen under vakuum og den vandige resten ekstraheres to ganger med dietyleter (for å fjerne uomsatt utgangsmate-riale), og den vandige fasen innstilles deretter med 12N saltsyre på pH-verdien 4,3. Den vandige fasen ekstraheres intenst med diklormetan. Ekstraktene samles, tørkes over natriumsulfat og konsentreres. På denne måten oppnås ca. 400 mg (ca. 46$) av forbindelsen av formel I, hvori R^ står for karboksy og R<2> for etoksykarbonyl, dvs. l-karboksymetyl-3S-(lS-etoksykarbonyl-3-fenylpropylamino)-2,3,4,5-tetrahydro-lH-[1]-benzazepin-2-on. To a solution of the diester mentioned under c) (1 g, 0.002 mol) in ethanol (10 ml) is added a solution of sodium carbonate (212 mg, 0.002 mol) in 8 ml of water, then a 1-molar solution of sodium hydroxide (1 .8 mL, 0.0018 mol). The mixture is stirred at room temperature and checked by EPLC (C 2 g column using a water - + methanol gradient over 20 minutes). When the reaction is complete, the ethanol is sucked off under vacuum and the aqueous residue is extracted twice with diethyl ether (to remove unreacted starting material), and the aqueous phase is then adjusted to pH 4.3 with 12N hydrochloric acid. The aqueous phase is intensively extracted with dichloromethane. The extracts are combined, dried over sodium sulfate and concentrated. In this way, approx. 400 mg (about 46$) of the compound of formula I, in which R^ stands for carboxy and R<2> for ethoxycarbonyl, i.e. 1-carboxymethyl-3S-(1S-ethoxycarbonyl-3-phenylpropylamino)-2,3, 4,5-tetrahydro-1H-[1]-benzazepin-2-one.
e) Fremstilling av forbindelsen av formel I hvori R<1> står for COOH og R<2> står for COOEt ( sure betingelser) e) Preparation of the compound of formula I in which R<1> stands for COOH and R<2> stands for COOEt (acidic conditions)
En suspensjon av den under c) omtalte diesteren (0,5 g, 0,01 mol) i 10 ml 4N saltsyre oppvarmes i ca. 4 timer til 50°C. Deretter er blandingen homogen og følges ved hjelp av HPLC (vann/metanol 25:75). På denne måten oppnås mer enn 88,5$ av den ønskede monoesteren av formel I. Blandingen avkjøles deretter og produktet utkrystalliseres. Krystallene frafiltreres og tørkes. På denne måten oppnås som råprodukt forbindelsen av formel I, hvori R^ står for karboksy og R<2 >for etoksykarbonyl, dvs. l-karboksymetyl-3S-(lS-etoksykarbonyl - 3-fenylpropylamino)-2,3,4, 5-tetrahydro-lH- [1] - benzazepin-2-on, som ifølge HPLC har en rehet på mer enn 96$ A suspension of the diester mentioned under c) (0.5 g, 0.01 mol) in 10 ml of 4N hydrochloric acid is heated for approx. 4 hours at 50°C. The mixture is then homogeneous and monitored by HPLC (water/methanol 25:75). In this way, more than 88.5% of the desired monoester of formula I is obtained. The mixture is then cooled and the product is crystallized. The crystals are filtered off and dried. In this way, the compound of formula I is obtained as a crude product, in which R^ stands for carboxy and R<2> for ethoxycarbonyl, i.e. 1-carboxymethyl-3S-(1S-ethoxycarbonyl-3-phenylpropylamino)-2,3,4,5 -tetrahydro-1H- [1]-benzazepin-2-one, which according to HPLC has a reh of more than 96$
(forurensningene er ca. 156 disyre og 2% diester). (the impurities are approx. 156 diacids and 2% diesters).
f) Fremstilling av forbindelsen av formel I hvori R^ og R<2 >står for COOH, som hvdrokloridsalt f) Preparation of the compound of formula I in which R 1 and R 2 are COOH, as the hydrochloride salt
Til en suspensjon av den under d) omtalte forbindelsen (1 g, 0,002 mol) i etanol (ca. 10 ml) tilsettes 4 ml av en 1,9N oppløsning av kaliumhydroksyd. Blandingen omrøres ved romtemperatur i 1 time, oppvarmes i 10 minutter til 50° C og avkjøles deretter. Etanolen avsuges under vakuum, og pH-verdien for den tilbakeblivende vandige oppløsningen innstilles med 12N saltsyre på 1. Det ønskede produktet utfelles fra oppløsningen. Produktet frafiltreres, vaskes med aceton og tørkes. På denne måten oppnås 600 mg av hydrokloridet av forbindelsen av formel I, hvori R<1> og R<2 >står for karboksy, frysepunkt 278-280°C. To a suspension of the compound mentioned under d) (1 g, 0.002 mol) in ethanol (approx. 10 ml) is added 4 ml of a 1.9N solution of potassium hydroxide. The mixture is stirred at room temperature for 1 hour, heated for 10 minutes to 50° C. and then cooled. The ethanol is sucked off under vacuum, and the pH value of the remaining aqueous solution is adjusted to 1 with 12N hydrochloric acid. The desired product is precipitated from the solution. The product is filtered off, washed with acetone and dried. In this way, 600 mg of the hydrochloride of the compound of formula I is obtained, in which R<1> and R<2> stand for carboxy, freezing point 278-280°C.
Eksempler 2- 4: Examples 2-4:
Eksempel 1 gjentas med det unntaket at R<1> i forbindelsen av formel II står for metoksykarbonyl, tert-butoksykarbonyl, hhv. karboksy. I det tilfellet at R<1> står for karboksy fører hydreringen av forbindelsen av formel III og omkrystalli-seringen fra aceton direkte til disyre. Example 1 is repeated with the exception that R<1> in the compound of formula II stands for methoxycarbonyl, tert-butoxycarbonyl, or carboxy. In the case that R<1> stands for carboxy, the hydrogenation of the compound of formula III and the recrystallization from acetone lead directly to the diacid.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86822786A | 1986-05-28 | 1986-05-28 |
Publications (4)
Publication Number | Publication Date |
---|---|
NO872226D0 NO872226D0 (en) | 1987-05-27 |
NO872226L NO872226L (en) | 1987-11-30 |
NO170489B true NO170489B (en) | 1992-07-13 |
NO170489C NO170489C (en) | 1992-10-21 |
Family
ID=25351280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO872226A NO170489C (en) | 1986-05-28 | 1987-05-27 | INTERMEDIATE FOR MANUFACTURING ACE INHIBITORS |
Country Status (10)
Country | Link |
---|---|
AT (1) | AT395008B (en) |
CA (1) | CA1284499C (en) |
DD (2) | DD263771A5 (en) |
DK (2) | DK167018B1 (en) |
ES (1) | ES2005880A6 (en) |
FI (1) | FI88723C (en) |
GR (1) | GR870819B (en) |
HU (2) | HU199832B (en) |
NO (1) | NO170489C (en) |
PT (1) | PT84947B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL139241A0 (en) | 1998-05-13 | 2001-11-25 | Novo Nordisk As | Meiosis regulating compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4410520A (en) * | 1981-11-09 | 1983-10-18 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
US4473575A (en) * | 1982-07-19 | 1984-09-25 | Ciba-Geigy Corporation | 3-Amino-(1)-benzazepin-2-one-1-alkanoic acids |
-
1987
- 1987-05-25 FI FI872306A patent/FI88723C/en not_active IP Right Cessation
- 1987-05-25 GR GR870819A patent/GR870819B/en unknown
- 1987-05-26 PT PT8494787A patent/PT84947B/en unknown
- 1987-05-26 CA CA000537949A patent/CA1284499C/en not_active Expired - Lifetime
- 1987-05-26 DD DD30316087A patent/DD263771A5/en not_active IP Right Cessation
- 1987-05-26 DD DD32522387A patent/DD278787A5/en not_active IP Right Cessation
- 1987-05-27 DK DK271087A patent/DK167018B1/en active IP Right Grant
- 1987-05-27 HU HU244487A patent/HU199832B/en unknown
- 1987-05-27 HU HU657987A patent/HU199807B/en unknown
- 1987-05-27 AT AT135787A patent/AT395008B/en not_active IP Right Cessation
- 1987-05-27 NO NO872226A patent/NO170489C/en unknown
- 1987-05-28 ES ES8701572A patent/ES2005880A6/en not_active Expired
-
1992
- 1992-10-27 DK DK130992A patent/DK169322B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
DK271087D0 (en) | 1987-05-27 |
DD278787A5 (en) | 1990-05-16 |
NO872226D0 (en) | 1987-05-27 |
FI872306A (en) | 1987-11-29 |
DK271087A (en) | 1987-11-29 |
HU199832B (en) | 1990-03-28 |
HUT44534A (en) | 1988-03-28 |
HU199807B (en) | 1990-03-28 |
GR870819B (en) | 1987-09-25 |
DK130992A (en) | 1992-10-27 |
DK167018B1 (en) | 1993-08-16 |
FI872306A0 (en) | 1987-05-25 |
DD263771A5 (en) | 1989-01-11 |
AT395008B (en) | 1992-08-25 |
DK169322B1 (en) | 1994-10-10 |
NO170489C (en) | 1992-10-21 |
PT84947A (en) | 1987-06-01 |
CA1284499C (en) | 1991-05-28 |
NO872226L (en) | 1987-11-30 |
DK130992D0 (en) | 1992-10-27 |
ES2005880A6 (en) | 1989-04-01 |
PT84947B (en) | 1990-02-08 |
FI88723B (en) | 1993-03-15 |
ATA135787A (en) | 1992-01-15 |
FI88723C (en) | 1993-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5068413A (en) | Process for the preparation of cyclic amino acids and intermediates useful in the process | |
JPH0694443B2 (en) | Amino acid derivative | |
BG60936B2 (en) | New derivatives of bicyclic amino acids, methods for their preparation, compositions containing them and their application, and new bicyclic amino acids as intermediate products, and methods for their preparation | |
EP0223744B1 (en) | Flavone derivatives | |
EP0331315A2 (en) | Preparation of R- and S-amlodipine | |
US5276164A (en) | Process for the production of 4-hydroxy-2-oxopyrrolidin-1-yl-acetamide | |
US5258525A (en) | Processes for preparing [2S-(2α,3aβ,7aβ)]octahydro-1H-indole-2-carboxylic acid and esters | |
CS274502B2 (en) | Method of glutaramide's derivatives' s-enantiomers production | |
NO170489B (en) | INTERMEDIATE FOR THE PREPARATION OF ACE INHIBITORS | |
HU206194B (en) | Process for producing cyclomethylene-1,2-dicarboxylic acid derivatives and pharmaceutical compositions comprising same | |
GB2077719A (en) | (N-(Cycloalkyl)amino acid compounds and compositions containing same | |
RU2709493C1 (en) | Method of producing roxadustat | |
GB2036744A (en) | Eburnane derivatives | |
US5028704A (en) | (2,5-dihydro 5-phenyl-2-oxo-3-furanyl)amines, methods of manufacture, and use thereof in the production of angiotensin converting enzyme inhibitors | |
AU725210B2 (en) | Preparation of 1-butyl-4-piperidinylmethylamine | |
JPH02172956A (en) | New process for producing erythro-3-(3,4-dihydroxyphenyl) serine derivative | |
US4918187A (en) | [2,5-Dihydro 5-phenyl-2-oxo-3-furanyl]amines | |
US7375245B2 (en) | N-(4-oxo-butanoic acid) -L-amino acid-ester derivatives and methods of preparation thereof | |
US4083850A (en) | 3-Substituted-2(1H)pyridon-6-carboxylic acids and process for preparation of same | |
US4704461A (en) | Processes and intermediates for sorbinil | |
KR910003184B1 (en) | The method uses proline derivatives | |
RU2034842C1 (en) | Quinoline derivative and a method of its synthesis | |
HU214581B (en) | N2-(1s)-(1-ethoxycarbonyl-3-phenylpropyl)-n6-trifluoro-acetyl-l-lysyl-l-proline-benzilester and process for producing it | |
US5675034A (en) | Process for preparing 2-(p-fluorophenyl)-2 methyl-propionic acid and 3-(p-fluorophenyl)-2-methylpropionic acid derivatives | |
US4156728A (en) | 3-Substituted-2(1H)pyridone-6-carboxylic acids |